Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hepatitis

HCV variability, the immune system and resistance to antiviral drugs

Nature Reviews Gastroenterology & Hepatology volume 6, pages 383–385 (2009)Cite this article

Several novel antiviral treatments for HCV are in preclinical or clinical development, and most target viral enzymes and their functions. These new drugs all potentially select for resistant viral variants, both in vitro and in vivo; viral resistance is, therefore, likely to become an important issue in clinical practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pawlotsky, J. M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 299, 261–284 (2006).

    CAS  PubMed  Google Scholar 

  2. Clavel, F. & Hance, A. J. HIV drug resistance. N. Engl. J. Med. 350, 1023–1035 (2004).

    Article  CAS  Google Scholar 

  3. Pawlotsky, J. M., Chevaliez, S. & McHutchison, J. G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132, 1979–1998 (2007).

    Article  CAS  Google Scholar 

  4. Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767–1777 (2007).

    Article  CAS  Google Scholar 

  5. Migliaccio, G. et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278, 49164–49170 (2003).

    Article  CAS  Google Scholar 

  6. Dutartre, H., Bussetta, C., Boretto, J. & Canard, B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues. Antimicrob. Agents Chemother. 50, 4161–4169 (2006).

    Article  CAS  Google Scholar 

  7. Coelmont, L. et al. Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor DEBIO-025. J. Hepatol. 50 (Suppl. 1), S36 (2009).

    Article  Google Scholar 

  8. Gaudieri, S. et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49, 1069–1082 (2009).

    Article  CAS  Google Scholar 

  9. Foster, G. R. et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis C patients: interim results of study C209. J. Hepatol. 50 (Suppl. 1), S22 (2009).

    Article  Google Scholar 

  10. Lawitz, E. et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J. Hepatol. 50 (Suppl. 1), S384 (2009).

    Article  Google Scholar 

  11. McCown, M. F., Rajyaguru, S., Kular, S., Cammack, N. & Najera, I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother. 53, 2129–2132 (2009).

    Article  CAS  Google Scholar 

  12. Kuntzen, T. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48, 1769–1778 (2008).

    Article  Google Scholar 

  13. Bartels, D. J. et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3/4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198, 800–807 (2008).

    Article  CAS  Google Scholar 

  14. Hezode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839–1850 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Department of Virology, Henri Mondor Hospital, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France jean-michel.pawlotsky@hmn.aphp.fr

Authors and Affiliations

  1. Department of Virology, National Reference Center for Viral Hepatitis B, C and D, INSERM, Henri Mondor Hospital, Créteil, France

    Jean-Michel Pawlotsky

Authors
  1. Jean-Michel Pawlotsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received research grants from Gilead Sciences, Roche, Schering-Plough and Vertex Pharmaceuticals. He has served as a Consultant for Abbott, AstraZeneca, Biotica, Boehringer-Ingelheim, Bristol-Myers Squibb, DebioPharm, Gilead Sciences, Glaxo-SmithKline, Jansen-Cilag, Madaus-Rottapharm, Merck, Novartis, Ono Pharma, Roche, Schering-Plough, Tibotec, Valeant and Vertex Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pawlotsky, JM. HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol 6, 383–385 (2009). https://doi.org/10.1038/nrgastro.2009.102

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2009.102

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing